Unable to Repeat the Autoimmune target in MS

Nerrant E, Salsac C, Charif M, Ayrignac X, Carra-Dalliere C, Castelnovo G, Goulabchand R, Tisseyre J, Raoul C, Eliaou JF, Labauge P, Vincent T. Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis. Mult Scler. 2014 Apr  [Epub ahead of print]
BACKGROUND. Auto-antibodies against the potassium channel inward rectifying potassium channel 4.1 (Kir4.1) have previously been identified in 46% of patients with multiple sclerosis (MS).

OBJECTIVES:to confirm these findings.

METHODS:we evaluated the presence of anti-Kir4.1 antibodies by enzyme-linked immunosorbent assay (ELISA) and immunofluorescence in 268 MS patients, 46 patients with other neurological diseases (OND) and 45 healthy controls.

RESULTS:anti-Kir4.1 antibodies were found in 7.5% of MS patients, 4.3% of OND patients and 4.4% of healthy controls. Immunofluorescence analysis did not identify any specific staining.

CONCLUSIONS:we confirmed the presence of anti-Kir4.1 antibodies in MS patients, but at a much lower prevalence than previously reported.

We knew this was arriving since it was documented in ECTRIMS some time ago. The original paper suggested that over 40% of MSers had antibodies against this molecule an ion channel. The frequency mentioned here is about tens times less. So back to the drawing board with regard to the nature of the autoantigen in MS. However, there will be more studies. Neverthe less it further shows there is an autoimmune component in MS.

This is science and replication is part of the process. Often it doesn’t replicate, but if it is real then people will replicate is and knowledge will move forward.

Wonder what Knowledge will come from this weeks AAN meeting in USA?. What do you think are the hot topics…you must have read the abstracts by now.

About the author



  • 4 [P4.342] B Cells from Blood of Patients with Relapsing-Remitting Multiple Sclerosis Induce Apoptosis in Neurons In Vitro
    Authors: Robert Lisak,1Liljana Nedelkoska,1Hanane Touil,2Joyce Benjamins,1Beverly Bealmear,1Riu Li,2Hetoum Misirliyan,2Amit Bar-Or,2

    1Detroit, MI, USA, 2Montreal, QC, Canada
    Date/Time: Wednesday, April 30, 2014 – 7:30 AM
    Session Info: P4: Poster Session IV: Child Neurology and Developmental Neurology IV (7:30 AM-11:00 AM)

    7 [I7-1.009] Laquinimod Reduces Neuronal Injury Through Inhibiting Microglial Activation
    Authors: Voon Wee Yong,1Manoj Mishra,1Janet Wang,1Michael Keough,1Claudia Silva,1Yan Fan,1Scott Sloka,1Liat Hayardeny2
    1Calgary, AB, Canada, 2Petach Tikva, Israel
    Date/Time: Wednesday, April 30, 2014 – 4:30 PM
    Session Info: I7: INS Poster Session: Emerging Therapeutic Advances in Multiple Sclerosis (2:00 PM-6:00 PM)

    Studies involving neurodegeneration. B cell supernatant induces neuronal apoptosis in rrms. Would be interesting to see impact on progressive disease.

  • Good Early Results for HERV Suppressor in MS:


    "After 12 monthly doses of the GNbAC1 antibody, targeting the so-called MRV-Env protein, seven patients with established MS (mean age 55, mean Expanded Disability Scale Score 4.8) showed stability in MRI brain lesion activity and no disability progression on average, according to Hervé Perron, PhD, of GeNeuro SA in Geneva, Switzerland, which is developing the drug."

    • The work is being presented at the AAN,let us hope that it is useful. GNbAC1 is a commercial antibody against HERV.

      Good press = investment

    • GNbAC1 seems to be succesful…what about INSPIRE study?
      Both of them works on EBV and HERV (more or less..)
      Seems also that Prof. Giovannoni, Prof. Gold and Prof. Pender are thinking in the right direction about cause of MS

By MouseDoctor



Recent Posts

Recent Comments